RAPT Therapeutics, Inc.

NASDAQ (USD): RAPT Therapeutics, Inc. (RAPT)

Last Price

1.74

Today's Change

+0.915 (110.90%)

Day's Change

1.46 - 2.32

Trading Volume

140,206,133

Profile
RAPT

Exchange:  NASDAQ Global Market NASDAQ Global Market

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Dr. Brian Russell Wong M.D., Ph.D. Dr. Brian Russell Wong M.D., Ph.D.

Full Time Employees:  70 70

IPO Date:  2019-10-31 2019-10-31

CIK:  0001673772 0001673772

ISIN:  US75382E1091 US75382E1091

CUSIP:  75382E109 75382E109

Beta:  0.32 0.32

Last Dividend:  0.00 0.00

Dcf Diff:  0.70 0.70

Dcf:  1.06 1.06

Description

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Address

561 Eccles Avenue,
South San Francisco, CA 94080, US

650 489 9000

http://www.rapt.com

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment